NCT07252232 · Interventional trial
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Overall registry status Recruiting
Phase 3
Conditions PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Resected Pancreatic Adenocarcinoma
Delaware Valley sites
- University of Pennsylvania, Abramson Cancer Center · Philadelphia, PA · Philadelphia County · Recruiting
First posted
Registry updated
Added to the directory